Wikidata

(Q63572409)

English

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.

clinical trial

In more languages

Statements

short name
HUDSON (English)
0 references
title
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON). (English)
0 references
sponsor
AstraZeneca
0 references
country
Austria
0 references
Canada
0 references
France
0 references
Germany
0 references
Israel
0 references
start time
18 December 2017
0 references
end time
30 July 2021
0 references
number of participants
260
0 references
research intervention
durvalumab
0 references
olaparib
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63572409&oldid=1857257780"